This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary MCTs Therapeutic Antibody Development
Background of MCTs
Cancer cells with high expression of MCTs are better equipped to maintain the pH levels necessary for tumor growth, making these transport proteins potential targets for therapeutic intervention. BioVenic has established a platform for the development of veterinary MCTs therapeutic antibodies, relying on skilled professionals and emerging technologies. We provide high-quality services that cover the entire antibody development process, from gene synthesis and antibody preparation to purification and characterization, assisting in exploring cancer treatment strategies for companion animals targeting MCTs.
Background of MCTs
| Full Name | Monocarboxylate transporters |
|---|---|
| Aliases | SLC16 |
| Target Profile | MCTs are members of the solute carrier 16 (SLC16) transporter family, playing a crucial role in the transport of short-chain monocarboxylates, hormones, nutrients, and amino acids. Due to their broad substrate specificity, these transport proteins are key in maintaining the steady state and functionality of endogenous molecules in circulation. The MCT family includes several members, with MCT1 and MCT4 exhibiting different expression patterns in various tissues and they are closely associated with a range of physiological and pathological processes. |
MoA of MCTs
The primary physiological function of MCTs 1-4 is the transport of monocarboxylates, including lactate, which helps maintain intracellular pH levels. In oncology, MCTs are particularly significant as they regulate lactate concentration within tumor cells. Tumor cells, even in the presence of sufficient oxygen, tend to undergo anaerobic glycolysis, producing large amounts of lactate. The elevated expression of MCTs in tumor cells assists in expelling excess lactate, thereby promoting tumor growth and survival.
Fig.1 Diagram of lactate transfer mediated by MCTs between cells.1, 2
Application in Veterinary Therapeutics
MCTs are highly expressed in various animal cancers, particularly in those tumors that are heavily reliant on glycolysis. MCT1 is rarely observed in the majority of melanocytes in normal canine oral mucosa, however, most canine oral melanomas express MCT1. The expression of MCT1 might play a significant physiological role in the survival of tumor cells within the microenvironment of oral melanoma tissue. Antibodies targeting MCTs can inhibit the function of MCTs, reducing the excretion of lactate by tumor cells, thereby disrupting the acidic microenvironment of the tumor and inhibiting tumor cell growth and spread. This could be effective in treating certain metabolically active companion animal tumors.
Veterinary MCTs Therapeutic Antibody Development Services
MCTs play a substantial role in some metabolically active solid tumors, hence antibody therapies targeting MCTs provide a novel treatment option for certain types of cancer in companion animals. BioVenic has established a diverse technology platform offering veterinary MCTs therapeutic antibody development services. We assist in developing veterinary therapeutic antibodies that can specifically bind to and regulate the activity of MCTs, providing safer and more effective treatment options for animals. Additionally, our services include antibody characterization and engineering to ensure the development of veterinary therapeutic antibodies with high affinity and safety.
Please click the link below for more information about our veterinary MCTs therapeutic antibody development services.
Why Choose Us?
We provide a one-stop solution for veterinary therapeutic antibody development, covering the entire process from antibody screening and preparation to engineering.
Our diverse technology platform offers a variety of choices, including traditional and cutting-edge techniques like hybridoma, single B cell, and phage display technologies.
Our team adheres to strict quality control to ensure the high purity and stability of antibody samples, aiding in better exploring the therapeutic potential of the antibodies.
MCTs are overexpressed in some types of companion animal cancers such as canine oral melanoma. BioVenic offers veterinary MCTs therapeutic antibody development services, encompassing not only antibody preparation but also precise engineering to ensure the high affinity and specificity of antibody samples. If you are considering developing veterinary MCTs therapeutic antibodies for animal cancer treatment, please contact us for more information!
References
- Liu, Tian, et al. "Role of human monocarboxylate transporter 1 (hMCT1) and 4 (hMCT4) in tumor cells and the tumor microenvironment." Cancer Management and Research (2023): 957-975.
- Image retrieved from Figure 3 "Schematic of lactate shuttling from cell to cell through the MCTs." Liu, Tian, et al., 2023, used under [CC BY 3.0], the image title was changed to "Diagram of lactate transfer mediated by MCTs between cells."